Global Cardiovascular Risk Consortium, Magnussen C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, Aviles-Santa L, Bakker SJL, et al. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates. N Engl J Med. 2025;393(2):125–38. https://doi.org/10.1056/NEJMoa2415879.

Article  Google Scholar 

Netala VR, Teertam SK, Li H, Zhang Z. A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells. 2024;13:1471. https://doi.org/10.3390/cells13171471.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moncho F, Benlloch S, Górriz JL. The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management. Clin Kidney J. 2025;18:sfaf260. https://doi.org/10.1093/ckj/sfaf260.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Souto Maior MDRM, Ribeiro NLI, Silva HVV, Lopes EP, Costa EC. Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review. Biomedicines. 2025;13(9):2162. https://doi.org/10.3390/biomedicines13092162.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pei Y, Goh GB-B. Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease. Gut Liver. 2025;19:8–18. https://doi.org/10.5009/gnl240407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanda T, Sasaki-Tanaka R, Abe H, Kimura N, Yoshida T, Hayashi K, et al. Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Narrative Review. Int J Mol Sci. 2025;26:5164. https://doi.org/10.3390/ijms26115164.

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD). European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492–542. https://doi.org/10.1016/j.jhep.2024.04.031.

Article  CAS  Google Scholar 

Chapter 1. Definition and classification of CKD. Kidney Int Suppl Elsevier. 2013;3:19–62. https://doi.org/10.1038/kisup.2012.64.

Article  Google Scholar 

Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–85. https://doi.org/10.1161/ATV.0000000000000153.

Article  CAS  PubMed  Google Scholar 

Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol Med. 2015;21:645–62. https://doi.org/10.1016/j.molmed.2015.08.005.

Article  CAS  PubMed  Google Scholar 

Gao Z, Deng H, Qin B, Bai L, Li J, Zhang J. Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease. Front Med (Lausanne). 2025;12:1539283. https://doi.org/10.3389/fmed.2025.1539283.

Article  PubMed  PubMed Central  Google Scholar 

Møller S, Kimer N, Hove JD, Barløse M, Gluud LL. Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects. Eur J Prev Cardiol. 2025;zwae306. https://doi.org/10.1093/eurjpc/zwae306.

GBD 2023 Cardiovascular Disease Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990–2023. J Am Coll Cardiol. 2025. https://doi.org/10.1016/j.jacc.2025.08.015. S0735-1097(25)07428-5.

Article  Google Scholar 

Ma H, Wang X, Xue Q, Li X, Liang Z, Heianza Y, et al. Cardiovascular Health and Life Expectancy Among Adults in the United States. Circulation. 2023;147:1137–46. https://doi.org/10.1161/CIRCULATIONAHA.122.062457.

Article  PubMed  PubMed Central  Google Scholar 

Mark PB, Stafford LK, Grams ME, Aalruz H, ElHafeez SA, Abdelgalil AA, et al. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10518):2461–82. https://doi.org/10.1016/S0140-6736(25)01853-7.

Article  Google Scholar 

Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic Fatty Liver Disease Incidence and Impact on Metabolic Burden and Death: a 20 Year-Community Study. Hepatology. 2018;67:1726–36. https://doi.org/10.1002/hep.29546.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ng CH, Lim WH, Lim GEH, Tan DJH, Syn N, Muthiah MD, et al. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21:931–e9395. https://doi.org/10.1016/j.cgh.2022.04.014.

Article  PubMed  Google Scholar 

Kan C, Zhang K, Wang Y, Zhang X, Liu C, Ma Y. Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990–2021 to 2045. Ann Hepatol. 2025;30(2):101898. https://doi.org/10.1016/j.aohep.2025.101898.

Article  PubMed  Google Scholar 

Global Cardiovascular Risk Consortium, Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, et al. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023;389:1273–85. https://doi.org/10.1056/NEJMoa2206916.

Article  Google Scholar 

Peng X, Jin C, Song Q, Wu S, Cai J. Stage 1 Hypertension and the 10-Year and Lifetime Risk of Cardiovascular Disease: A Prospective Real‐World Study. J Am Heart Assoc. 2023;12:e028762. https://doi.org/10.1161/JAHA.122.028762.

Article  PubMed  PubMed Central  Google Scholar 

Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625–36. https://doi.org/10.1016/S0140-6736(21)00590-0.

Article  Google Scholar 

Zheng Y, Gao X, Jia H-Y, Li F-R, Ye H. Influence of hypertension duration and blood pressure levels on cardiovascular disease and all-cause mortality: A large prospective cohort study. Front Cardiovasc Med. 2022;9:948707. https://doi.org/10.3389/fcvm.2022.948707.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wen CP, Lu PJ, Gao W, Lee JH. The cardiovascular disease risk of hypertensive smokers. Tob Induc Dis. 2021;19(1):A216. https://doi.org/10.18332/tid/141425.

Article  Google Scholar 

Lai Y, Long H, Liang Z, Wu C, Wu L, Liu C, et al. Global burden and risk factors of chronic kidney disease due to hypertension in adults aged 20 plus years, 1990–2021. Front Public Health. 2025;13:1503837. https://doi.org/10.3389/fpubh.2025.1503837.

Article  PubMed  PubMed Central  Google Scholar 

Liu KS, Wang B, Mak IL, Choi EP, Lam CL, Wan EY. Early onset of hypertension and increased relative risks of chronic kidney disease and mortality: two population-based cohort studies in United Kingdom and Hong Kong. Hypertens Res. 2025;48:1963–71. https://doi.org/10.1038/s41440-025-02188-x.

Article  CAS  PubMed  Google Scholar 

Qiu L, Wu B. The relationship between the age of onset of hypertension and chronic kidney disease: a cross-sectional study of the American population. Front Cardiovasc Med. 2024;11:1426953. https://doi.org/10.3389/fcvm.2024.1426953.

Article  PubMed  PubMed Central  Google Scholar 

Kidney Disease. Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99:S1–87. https://doi.org/10.1016/j.kint.2020.11.003.

Article  Google Scholar 

Zhuo M, Yang D, Goldfarb-Rumyantzev A, Brown RS. The Association of Systolic Blood Pressure with Mortality in Patients with Stage 1–4 Chronic Kidney Disease. J Hypertens. 2021;39:2250–7. https://doi.org/10.1097/HJH.0000000000002927.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of Intensive BP Control in CKD. J Am Soc Nephrol. 2017;28:2812–23. https://doi.org/10.1681/ASN.2017020148.

Article  PubMed  PubMed Central  Google Scholar 

Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, et al. Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. JAMA Intern Med. 2017;1